Journal
BIOMATERIALS
Volume 30, Issue 23-24, Pages 4014-4020Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2009.04.011
Keywords
In vivo gene transfer; Nonviral vector; Combined gene therapy; PEI PEGylation; Glioma; Tumor targeting
Funding
- 863 Programs of China [2007AA021101]
- National Science Foundation of China (NSFC) [30672411, 50673103, 50830107]
- Ministry of Education of China [20050558084, 20060558083]
- Research Grant Council (RGC) of Hong Kong [CUHK7394/04M]
Ask authors/readers for more resources
Combined treatment using nonviral agent-mediated enzyme/prodrug therapy and immunotherapy had been proposed as a powerful alternative method of cancer therapy. The present study was aimed to evaluate the cytotoxicity in vitro and the therapeutic efficacy in vivo when the cytosine deaminase/5-fluorocytosine (CD/5-FC) and TNF-related apoptosis-inducing ligand (TRAIL) genes were jointly used against rat C6 glioma cells. The potency of the FA-PEG-PEI used as a nonviral vector was tested in the FR-expressed C6 glioma cells and Wistar rats. The C6 glioma cells and animal model were treated by the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL. The antitumor effect was evaluated by survival assays and tumor volume. This study revealed a significant increase of cytotoxicity in vitro following the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL treatments in C6 glioma cells. Animal studies showed a significant growth inhibition of the C6 glioma xenografts using the combined treatment. These results demonstrated that the combined treatment generated additive cytotoxic effect in C6 glioma cells in both in vitro and in vivo conditions, and indicated that such treatment method using both enzyme/prodrug therapy and TRAIL immunotherapy might be a promising therapeutic strategy in treating glioma. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available